Allergan gains US FDA nod for Botox in overactive bladder

Allergan racked up another indication for Botox (onabotulinumtoxinA) – known mostly for its antiwrinkle capabilities – this time to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency and frequency but are unable to use or have had an inadequate response to anticholinergics.

Allergan racked up another indication for Botox (onabotulinumtoxinA) – known mostly for its antiwrinkle capabilities – this time to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency and frequency but are unable to use or have had an inadequate response to anticholinergics.

The latest win makes it the eighth medical indication for Botox in the US, the Irvine, California-based company said.

More from Dermatological

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

More from Therapeutic Category